Picot S
EA 37-32, virulence et résistance de plasmodium, faculté de médecine de Lyon, université Claude-Bernard, 69373 Lyon, France.
Med Mal Infect. 2006 Aug;36(8):406-13. doi: 10.1016/j.medmal.2006.06.001. Epub 2006 Jul 13.
P. vivax is supposed to be involved in benign tertian fever, responsible for a non-complicated disease that could be easily treated by standard antimalarial drug regimen. This could be considered as a long-standing paradigm of a non-virulent malaria parasite. When a patient exhibits severe malaria with the vivax parasite, the issue is often to find falciparum. However, with the implementation of molecular diagnosis, it has becoming more evident that vivax parasites could be involved in severe disease with probably a different pathogenesis. Mixed infections are frequent in various parts of Southeast Asian endemic areas and it was speculated that drugs used to treat falciparum could be involved in the development of vivax drug resistance. How should primaquine be used today for the treatment and prophylaxis of vivax malaria? Considering the re-emergence of vivax malaria in several areas, improving the treatment for this disease is certainly an important issue to avoid late episodes and transmission potential.
间日疟原虫被认为与良性三日热有关,引发的疾病并不复杂,采用标准抗疟药物治疗方案即可轻松治愈。这可被视为非致病性疟原虫的长期范例。当患者感染间日疟原虫却表现出严重疟疾症状时,问题往往在于是否合并感染了恶性疟原虫。然而,随着分子诊断技术的应用,越来越明显的是,间日疟原虫可能通过不同的发病机制引发严重疾病。在东南亚疟疾流行地区的各个地方,混合感染很常见,有人推测用于治疗恶性疟原虫的药物可能与间日疟原虫耐药性的产生有关。如今,伯氨喹应如何用于间日疟的治疗和预防呢?鉴于间日疟在多个地区再度出现,改进这种疾病的治疗方法无疑是一个重要问题,以避免出现晚期发作和传播风险。